Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Normanno N"'
Autor:
Cardone C., Blauensteiner B., Moreno-Viedma V., Martini G., Simeon V., Vitiello P. P., Ciardiello D., Belli V., Matrone N., Troiani T., Morgillo F., Zito Marino F., Dentice M., Nappi A., Boccaccino A., Antoniotti C., Cremolini C., Pietrantonio F., Prager G. W., Normanno N., Maiello E., Argiles G., Elez E., Signoriello G., Franco R., Falcone A., Tabernero J., Sibilia M., Ciardiello F., Martinelli E., ZITO MARINO, Federica
Background RAS mutations are the only validated biomarkers in metastatic colorectal cancer (mCRC) for anti-epidermal growth factor receptor (EGFR) therapy. Limited clinical information is available on AXL expression, marker of epithelial to mesenchym
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4937b3b9337afc85a90006c6268b2a74
https://hdl.handle.net/11588/920571
https://hdl.handle.net/11588/920571
Autor:
Guglielmo Nasti, Chiara Carlomagno, Carmela Romano, Francesco Perrone, Sabino De Placido, Tizana Pia Latiano, Maria Carmela Piccirillo, Domenico Bilancia, Pasqualina Giordano, Lucrezia Silvestro, Oscar Alabiso, Antonio Avallone, Nicola Normanno, Anna Nappi, Alessandro Ottaiano, Alfonso De Stefano, Gerardo Rosati, Evaristo Maiello, Bruno Daniele, Antonino Cassata, Rosario Vincenzo Iaffaioli
Publikováno v:
Clinical Colorectal Cancer. 19:270-276
Purpose: To assess whether panitumumab is active in patients with cetuximab-refractory metastatic colorectal cancer (mCRC). Patients and Methods: Eligible patients had pretreated RAS (renin–angiotensin system) wild-type mCRC that progressed after c
Autor:
Francesco Izzo, Anna Maria Trotta, Vittorio Albino, Lucrezia Silvestro, Antonio Avallone, Raffaele Palaia, Gerardo Botti, Monica Capozzi, Paolo Chiodini, Rossana Casaretti, Carmine Picone, Stefania Scala, Nicola Normanno, Mario Tamburini, Andrea Belli, Crescenzo D'Alterio, Anna Maria Rachiglio, Massimiliano Di Marzo, Guglielmo Nasti, Paolo Delrio, Cristin Roma, Anna Nappi, Carmela Romano, Antonella Petrillo, Antonino Cassata, Gianfranco De Feo, Alessandro Ottaiano, Salvatore Tafuto, Maria Napolitano, Alfonso Amore, Alfonso De Stefano, Ugo Pace, Luigi Portella
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-9 (2019)
BMC Cancer
BMC Cancer
Background Combination of chemotherapies (fluoropirimidines, oxaliplatin and irinotecan) with biologic drugs (bevacizumab, panitumumab, cetuximab) have improved clinical responses and survival of metastatic colorectal cancer (mCRC). However, patients
Autor:
Erika Martinelli, Teresa Troiani, Lucia Esposito, Nicola Normanno, Davide Ciardiello, Carmine Pinto, Evaristo Maiello, Chiara Cremolini, Tiziana Latiano, Vincenzo Famiglietti, Giuseppe Santabarbara, Giulia Martini, Antonio Avallone, Stefania Napolitano, Fortunato Ciardiello, Filippo Pietrantonio
Publikováno v:
Cancers
Volume 13
Issue 22
Cancers, Vol 13, Iss 5715, p 5715 (2021)
Volume 13
Issue 22
Cancers, Vol 13, Iss 5715, p 5715 (2021)
The single-arm phase II CAVE mCRC trial evaluated the combination of cetuximab plus avelumab as rechallenge strategy in RAS wild-type (WT) metastatic colorectal cancer (mCRC) patients, with clinical response to first-line anti-EGFR-based chemotherapy
Autor:
Teresa Troiani, Federica Morano, M. Terminiello, Giuseppe Santabarbara, Evaristo Maiello, Davide Ciardiello, Carmine Pinto, Anna Nappi, Erika Martinelli, Vincenzo Famiglietti, Claudia Cardone, Alessandra Di Liello, C. Borrelli, Chiara Cremolini, Antonio Avallone, Filippo de Braud, Stefania Napolitano, N. Zanaletti, Daniela Renato, Lucia Esposito, Daniele Santini, Filippo Pietrantonio, Tiziana Latiano, Giulia Martini, Pietro Paolo Vitiello, Nicola Normanno, Francesca Marrone, Daniele Rossini, Fortunato Ciardiello, Alfredo Falcone
Publikováno v:
JAMA Oncol
IMPORTANCE: Rechallenge therapy with anti–epidermal growth factor receptor (EGFR) drugs has been suggested in patients with chemo-refractory RAS wild-type (WT) metastatic colorectal cancer (mCRC) after initial response to anti–EGFR-based first-li
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60be67165de23d28a233b66cf2cd6dac
http://hdl.handle.net/11568/1113694
http://hdl.handle.net/11568/1113694
Autor:
Teresa Troiani, Giulia Martini, F. De Vita, Claudia Cardone, Tiziana Latiano, Fortunato Ciardiello, Evaristo Maiello, Nicola Normanno, Erika Martinelli, Anna Maria Rachiglio, Pietro Paolo Vitiello, Davide Ciardiello
Epidermal growth factor receptor (EGFR) inhibitors are valuable therapeutics in metastatic colorectal cancer (mCRC). Anti-EGFR monoclonal antibodies (MoAbs), such as cetuximab or panitumumab, in combination with chemotherapy are effective treatment o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5fc1e2145074e4fd31c7a3f556eb19ea
http://hdl.handle.net/11591/427752
http://hdl.handle.net/11591/427752
Autor:
Giovanni Scambia, Cosimo Sacco, Giorgio Valabrega, Maria Carmela Piccirillo, Antonella Savarese, Pierosandro Tagliaferri, Rossella Lauria, Francesco Perrone, Ugo De Giorgi, Sabrina Chiara Cecere, Marilena Di Napoli, Saverio Cinieri, Gabriella Ferrandina, Ciro Gallo, Giulia Amadio, Maria Ornella Nicoletto, Vanda Salutari, Nicola Normanno, Sandro Pignata, Domenica Lorusso, Simona Losito, Giuseppa Maltese, Gennaro Daniele, Anna Maria Mosconi, Claudia Omarini, Alessandra Sacco, Carmela Pisano, Stefano Greggi, Simona Signoriello, Barbara Kopf, Francesco Raspagliesi
Publikováno v:
Gynecologic oncology. 153(3)
Background Cervical cancer cells often express Epidermal Growth Factor Receptor (EGFR). Cetuximab (CET), an anti-EGFR antibody, can be safely combined with carboplatin (C) and paclitaxel (P), a standard treatment for advanced/recurrent cervical cance
Autor:
Silvana Leo, A. Rinaldi, Francesco Giuliani, Salvatore Pisconti, R. Esposito Abate, Alessia Iannaccone, Fortunato Ciardiello, Matilde Lambiase, Anna Maria Rachiglio, Evaristo Maiello, E. Martinelli, Nicola Normanno, M. Biglietto, Laura Forgione, Teresa Troiani, Tiziana Latiano, Roberto Bordonaro, Claudia Cardone, D. Rizzi, Alessandra Sacco
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 29(1)
Background Liquid biopsy is an alternative to tissue for RAS testing in metastatic colorectal carcinoma (mCRC) patients. Little information is available on the predictive role of liquid biopsy RAS testing in patients treated with first-line anti-EGFR
Autor:
Andrea Onetti Muda, Guido Giordano, Gianni Simone, Pietro Micheli, C. Barone, Giacomo Cartenì, Fabiana Tatangelo, Laura Longhitano, Vincenzo Rosario Iaffaioli, Alessandra Cassano, M. Biglietto, Anna Nappi, Sabrina Rossi, A.R. Bordonaro, A. Rinaldi, Francesco Sponziello, G. Modoni, GabrieleDi Maggio, Matilde Lambiase, Oscar Nappi, Claudia Cardone, Antonella Marino, Mirko Montrone, Sandro Barni, Michele Orditura, Antonio Febbraro, Paolo Graziano, Saverio Cinieri, Guglielmo Nasti, Fortunato Ciardiello, Evaristo Maiello, D. Rizzi, Vincenzo Sforza, Stefano Cordio, F. De Vita, Erika Martinelli, S. Romito, Vincenzo Montesarchio, Giuseppe Tonini, Annamaria Sebastio, Salvatore Pisconti, Nicola Normanno, Tiziana Guarino, Giuseppe Colucci, Francesco Giuliani, Anna Maria Rachiglio, Gerardo Botti, Nicoletta Chicchinelli, Tiziana Latiano, Teresa Troiani, Vito Lorusso, Michele Aieta, Silvana Leo, Giuseppe Grimaldi, Eugenio Tommaselli, Luigi Leo, Cinzia Chiarazzo, Mario Manusia
Publikováno v:
ESMO Open
In the cetuximab after progression in KRAS wild-type colorectal cancer patients (CAPRI) trial patients with metastatic colorectal cancer (mCRC) received 5-fluorouracil, folinic acid and irinotecan (FOLFIRI) and cetuximab in first line followed by 5-F
Autor:
Francesco Sponziello, Saverio Cinieri, Giuseppe Grimaldi, Alessandra Cassano, M. Biglietto, Pietro Micheli, Gianni Simone, C. Barone, Fabiana Tatangelo, Antonella Marino, Giacomo Cartenì, Guglielmo Nasti, D. Rizzi, Antonio Febbraro, Cinzia Chiarazzo, Mario Manusia, Vito Lorusso, Fortunato Ciardiello, A.R. Bordonaro, S. Romito, Sabrina Rossi, Teresa Troiani, F. De Vita, Eugenio Tommaselli, Giuseppe Colucci, Andrea Onetti Muda, Guido Giordano, Luigi Leo, G. Modoni, Annamaria Sebastio, Sandro Barni, Francesco Giuliani, Paolo Graziano, M. Rachiglio, Michele Aieta, Evaristo Maiello, Enrica Martinelli, Mirko Montrone, Silvana Leo, Tiziana Latiano, Stefano Cordio, Laura Longhitano, Vincenzo Rosario Iaffaioli, Vincenzo Montesarchio, Nicola Normanno, Anna Nappi, Matilde Lambiase, Gerardo Botti, Gabriele Di Maggio, Giuseppe Tonini, Nicoletta Chicchinelli, Oscar Nappi, Claudia Cardone, Michele Orditura, A. Rinaldi, Salvatore Pisconti, Tiziana Guarino
Background Cetuximab plus chemotherapy is a first-line treatment option in metastatic KRAS and NRAS wild-type colorectal cancer (CRC) patients. No data are currently available on continuing anti-epidermal growth factor receptor (EGFR) therapy beyond
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::343fea2703fb6409297f48937f6f6bde
http://hdl.handle.net/11591/354385
http://hdl.handle.net/11591/354385